InVitae (NVTA) Now Covered by Analysts at Ladenburg Thalmann Financial Services
Analysts at Ladenburg Thalmann Financial Services started coverage on shares of InVitae (NYSE:NVTA) in a research report issued to clients and investors on Friday. The brokerage set a “buy” rating and a $15.00 price target on the medical research company’s stock. Ladenburg Thalmann Financial Services’ target price points to a potential upside of 52.75% from the stock’s current price.
Several other equities analysts also recently issued reports on the stock. Zacks Investment Research downgraded shares of InVitae from a “hold” rating to a “sell” rating in a report on Thursday. BidaskClub downgraded shares of InVitae from a “buy” rating to a “hold” rating in a report on Thursday, October 26th. Finally, Leerink Swann cut their price target on shares of InVitae from $14.00 to $12.00 and set an “outperform” rating for the company in a report on Tuesday, November 7th. Three investment analysts have rated the stock with a sell rating and four have issued a buy rating to the company. The stock has an average rating of “Hold” and an average price target of $13.80.
Shares of InVitae (NYSE:NVTA) traded up $0.29 during trading on Friday, hitting $9.82. 383,700 shares of the stock traded hands, compared to its average volume of 349,033. The company has a debt-to-equity ratio of 0.33, a quick ratio of 2.61 and a current ratio of 2.61. InVitae has a 1-year low of $2.70 and a 1-year high of $9.90. The firm has a market cap of $504.57, a price-to-earnings ratio of -3.84 and a beta of 1.30.
WARNING: This news story was published by American Banking News and is the sole property of of American Banking News. If you are reading this news story on another site, it was stolen and republished in violation of US and international trademark and copyright law. The legal version of this news story can be viewed at https://www.americanbankingnews.com/2018/01/05/invitae-nvta-now-covered-by-analysts-at-ladenburg-thalmann-financial-services.html.
InVitae Company Profile
Invitae Corporation utilizes an integrated portfolio of laboratory processes, software tools and informatics capabilities to process deoxyribonucleic acid (DNA)-containing samples, analyze information about patient-specific genetic variation and generate test reports for clinicians and their patients.
Receive News & Ratings for InVitae Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InVitae and related companies with MarketBeat.com's FREE daily email newsletter.